Exclusion criteria: <br>•Liver disease as indicated by ASAT = 3 x ULN (= 5 x ULN if liver involvement is present)<br>•Patients who have a history of another primary malignancy = 3 years, with the exception of non-melanoma skin cancer, completely resected melanoma TNMpT1 and carcinoma in situ of uterine cervix.<br>•Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Oral contraceptives are not acceptable.<br>•Patients unwilling to or unable to comply with the protocol.<br>•Patients who are using other investigational agents or who had received investigational drugs = 4 weeks prior to study drug start.<br>•Patients who had myelosuppressive chemotherapy or biologic therapy < 2 weeks to study inclusion.<br>•Patients who have previously received systemic mTOR inhibitor (sirolimus, temsirolimus, everolimus, etc).<br>•Patients with evidence of current central nervous system (CNS) involvement.<br>•Patients receiving chronic systemic immunosuppressive agents. Inhaled and topical steroids are acceptable. Patients may be receiving stable (not increased within the last month) chronic doses of corticosteroids with a maximum dose of 20 mg of prednisone or 10 mg of dexamethasone per day, if they are being given for disorders other than lymphoma such as rheumatoid arthritis, polymyalgia rheumatica or adrenal insufficiency or asthma.<br>•Patients with active, bleeding diathesis.<br>•Patients with known hypersensitivity to  everolimus or other rapamycins (sirolimus, temsirolimus) or to any protocol medication.<br>•Patients receiving ongoing radiation therapy<br>•Patients with a psychiatric, addictive or any disorder which compromises their ability to give truly informed consent for participation in this study.<br>•Non-compliance: Refusal of blood products during treatment, epilepsy, drug dependency, change of residence to abroad, prior cerebral injury or similar circumstances that appear to make protocol treatment or long-term follow-up impossible<br>•Antiepileptic treatment<br>•poorly controlled diabetes as defined by fasting serum glucose >2.0 x ULN<br>•Patients with a known history of HIV seropositivity, chronic active hepatitis<br>•Patients who have a relationship of dependence or employer-employee relationship to the sponsor or the investigator<br>•Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:<br>–unstable angina pectoris, symptomatic congestive heart failure (NYHA II, III, IV), myocardial infarction = 6 months prior to first study drug, serious uncontrolled cardiac arrhythmia, cerebrovascular accidents = 6 months before study drug start<br>–severely impaired lung function as defined by spirometry (FEV1) and DLCO (diffusing capacity of the lung for carbon monoxide) that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air<br>–any active (acute or chronic) or uncontrolled infection/disorders that impair the ability to evaluate the patient or for the patient to complete the study<br>–nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by this study drug, such as severe hypertension that is not controlled with medical management and thyroid abnormalities whose thyroid function cannot be maintained in the normal range by medication<br>